Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

RIPAIR A possible new role of type I interferon (IFN)-mediated survival of influenza A virus (IAV)-infected lung cells in lung repair

Coordinator
Universitaetsklinikum Freiburg, Germany
Runs
1 June 2027 to 31 May 2029
Status
Running
EU funding
€218k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101273281

What the project is doing

In the project's own words, from its summary on CORDIS.

Lower respiratory tract infections caused by influenza viruses remain a leading cause of morbidity and mortality worldwide and predispose individuals to secondary respiratory disease. Type I interferon (IFN) protects against severe disease by blocking or restricting viral replication before the immune system clears those infected cells. However, a new concept has emerged from studies done in mice, suggesting that a significant proportion of lung progenitor cells survive influenza A virus (IAV) infection in an IFN-dependent manner without clearance.

The RIPAIR project will investigate the relevance and function of these IAV-survivor cells in lung repair, by studying if (i) a specific innate immune response in progenitor cells mediates their preferential resistance to IAV, (ii) these surviving progenitor cells enhance the lung's ability to regenerate, and (iii) these survivor progenitor cells are also present in human lung tissue after IAV infection, where they contribute to tissue repair.

Understanding these mechanisms is critical as failing repair might negatively impact cell survival (“RIP air”). This project combines the expertise of an aspiring young researcher trained in viral immunopathogenesis with that of an experienced host specialized in IAV biology and long-term RNA virus consequences. Using state-of-the-art mouse and human lung organoid systems, genetically engineered in vivo models, and unbiased RNA sequencing, RIPAIR will visualize and functionally characterize survivor progenitor cells to uncover if and how they contribute to tissue recovery, both in an animal and human model.

In the long term, this basic research project may inspire new directions for identifying targets that support lung recovery after IAV infection. Simultaneously, RIPAIR will provide advanced training in cutting-edge methodologies, foster interdisciplinary collaboration, and strengthen the fellow’s career development within an international and stimulating research environment.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum FreiburgFreiburgGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI